title: hERG Channels: From Antitargets to Novel Targets for Cancer Therapy.
abstract: In this issue of Clinical Cancer Research, evidence is provided on how to avoid cardiotoxicity when targeting hERG K+channel for cancer therapy. hERG regulates different aspects of neoplastic progression. Although its blockade has effective anticancer effects in experimental models, it may lead to fatal arrhythmias in humans. Clin Cancer Res; 23(1); 3-5. ©2016 AACRSee related article by Pointer et al., p. 73.
authors.affiliation: Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. annarosa.arcangeli@unifi.it.
authors.forename: Annarosa
authors.initials: A
authors.lastname: Arcangeli
authors.affiliation: Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Becchetti
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D051638:Ether-A-Go-Go Potassium Channels / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D006801:Humans; D058990:Molecular Targeted Therapy; D026902:Potassium Channel Blockers / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D051638:Ether-A-Go-Go Potassium Channels; D026902:Potassium Channel Blockers